4-6 g PO daily
3-4 g PO daily
2-4 g PO daily
540 mg-2.8 g PO daily
CAD, eczema (atopic), endometriosis, GI disorders, hypercholesterolemia, intermittent claudication, mastalgia, menopausal symptoms, osteoporosis, premenstrual syndrome, rheumatoid arthritis
Possibly effective for PMS, mastalgia, osteoporosis
Frequency Not Defined
Bleeding disorders, concomitant anesthesia, schizophrenia, seizure disorder
Pregnancy & Lactation
Pregnancy Category: X
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Gamma-linolenic acid (GLA) metabolized to anti-inflammatory prostaglandins